MNPR Monopar Corp Earnings per share for the last twelve months

MNPR (Monopar Therapeutics Inc) - company brandmark

Monopar Therapeutics (MNPR) has fully outsourced drug production to contract manufacturers to optimize costs. The TTM annual earnings per share on the GURU.Markets daily chart demonstrates financial stability, where -2.57 shows the current value of the metric. R&D efficiency allows for a lean staff of leading scientists, while growth potential is fueled by camsirubicin trials and the development of radiopharmaceuticals.

MNPR (Monopar Therapeutics) Net earnings per share for the last 12 months history from 07/04/2022 to 11/15/2026

Monopar Corp - analytical breakdowns and key metrics (MNPR)

- current quotes and average value forecast:
Basic company analysis:monopartx.com (MNPR)
Mass-produced product of Monopar Pharma

Professional issuer selection is based on an analysis of a business's ability to generate real income, with the efficiency of profit distribution among shareholders serving as the key filter. This 12-month net income per share history reflects the annual financial result of a single security, which for Monopar Therapeutics (MNPR), given its early-stage oncology drug development, indicates an investment phase and a lack of current operating revenue.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|INBX (inhibrx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months i-mabbiopharma.com (IMAB)|Earnings per share for the last twelve months Fennec (FENC)|HRTX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Nuvectis NVCT|Coherus Biosciences - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months cardiffoncology.com|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla, Inc. BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharmaceuticals, Inc. CTXR|Net earnings per share for the last 12 months CLRB (Cellectar Biosciences)|BLRX (BioLineRx) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months